chrisvoncsefalvay/vaers-outcomes huggingface dataset:
she had no taste or smell; she had no taste or smell; tiny bit of nausea; little bit tired still; This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (she had no taste or smell), ANOSMIA (she had no taste or smell), NAUSEA (tiny bit of nausea) and FATIGUE (little bit tired still) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Feb-2021, the patient experienced AGEUSIA (she had no taste or smell), ANOSMIA (she had no taste or smell), NAUSEA (tiny bit of nausea) and FATIGUE (little bit tired still). On 06-Feb-2021, NAUSEA (tiny bit of nausea) outcome was unknown. At the time of the report, AGEUSIA (she had no taste or smell), ANOSMIA (she had no taste or smell) and FATIGUE (little bit tired still) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Feb-2021, SARS-CoV-2 test negative: negative negative and negative negative. On 03-Feb-2021, SARS-CoV-2 test positive: positive positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No specific concomitant medications given for high blood pressure.  No treatment information was provided.
Started experiencing sensitivity to heat and cold, later diagnosed with Raynaud's, swelling of hands and feet in heat, lack of blood to extremities in cold, severe pain in hands, periods went from light with no cramping to heavy bleeding and almost constant,  developed an allergy which started with blisters on hands and feet and is now on her whole body when exposed to the sun, achy body, asthma worsened
March 30th MMR vaccine. April 10th rash & severe itching. Ongoing with itching.
Patient received a dose of Pfizer pediatric COVID-19 vaccine that had been diluted the previous day; therefore vaccine was considered expired or outside it's range of stability.
Information has been received from a physician concerning a 25 year old female with no pertinent medical history or allergies who on 21-NOV-2008 was vaccinated intramuscularly in her right deltoid with 0.5 ml third dose of GARDASIL (lot # 660557/0072X). Concomitant therapy included an unspecified birth control medication. On 21-NOV-2008 the patient developed an induration "about the size of a dime" at the injection site of the right deltoid muscle. The area was painful to touch, The physician added that the patient had a similar knot near her vagina. The patient contacted the office via phone. No laboratory or diagnostics test were performed. At the time of this report, as 18-DEC-2008, the events persisted. Additional information has been requested.
confusion; can't walk; hurts all over; rash on arm; This spontaneous case was reported by a consumer and describes the occurrence of CONFUSIONAL STATE (confusion), GAIT INABILITY (can't walk), PAIN (hurts all over) and RASH (rash on arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced CONFUSIONAL STATE (confusion), GAIT INABILITY (can't walk), PAIN (hurts all over) and RASH (rash on arm). At the time of the report, CONFUSIONAL STATE (confusion), GAIT INABILITY (can't walk), PAIN (hurts all over) and RASH (rash on arm) outcome was unknown.            No concomitant medications were provided by the reporter.   Treatment information was not provided.
FU info received states pt experienced nausea and vomiting and was diagnosed with viral illness. He then went to Guatemala and his nausea and anorexia continued. He was seen by a physician and found to have slightly jaundiced sclera and increased bilirubin. He was tentatively diagnosed with hepatitis A, blood tests were negative.
Patient received the Moderna bivalent booster as their first dose prior to primary series vaccine; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent booster as their first dose prior to primary series vaccine) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     It was unknown whether the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent booster as their first dose prior to primary series vaccine) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent booster as their first dose prior to primary series vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent booster as their first dose prior to primary series vaccine).    No concomitant medications were provided. No treatment medication was provided.
Patient received monovalent pfizer instead of bivalent pfizer for booster dose. No adverse events.
After vaccine I had a headache and was lethargic and took Tylenol, next day I took Tylenol and Movic and started feeling better but yesterday I got this nodule on my neck that I can move around. My lymph node is enlarged
grade 3 fevers; chills; myalgias; arthralgias; fatigue; This is a spontaneous report from a contactable Physician. This 68-years-old male Physician reported for himself that she received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 04Feb2021 (Batch/Lot Number: EN5318) as SINGLE DOSE for COVID-19 immunisation. Medical history included arteriosclerosis coronary artery from 2006 to an unknown date, osteoarthritis, hypercholesterolaemia, benign prostatic hyperplasia, upper limb fracture from 2018 to an unknown date, joint dislocation from 2018 to an unknown date, radial head dislocation from 2020 to an unknown date. Also, had a radial head replacement 3 months prior to vaccination and developed severe pain at the prosthesis site. Concomitant medications included aspirin [acetylsalicylic acid] (ASPIRIN [ACETYLSALICYLIC ACID]) taken for an unspecified indication, start and stop date were not reported; rosuvastatin (ROSUVASTATIN) taken for an unspecified indication, start and stop date were not reported; tadalafil (TADALAFIL) taken for an unspecified indication, start and stop date were not reported. On 04Feb2021 16:00 the patient experienced grade 3 fevers, chills, myalgias, arthralgias, fatigue. The action taken in response to the events for bnt162b2 was not applicable. The outcome of the events was reported as recovered. The outcome of the events was reported as recovered. Therapeutic measures were taken as a result of grade 3 fevers (pyrexia), chills (chills), myalgias (myalgia), arthralgias (arthralgia), fatigue (fatigue).
About 15 hours after vaccination, severe chills and tremors, chills lasted for approx 4 hours, tremors approx 1 hour. Bladder was very full twice during the night, not normal, I usually sleep through the night without needing to urinate. 20 hours post vaccination, body is sore and weak, headache, neck is sore. At present, still feeling dehydrated, head feels really heavy, very hungry.
GASSY FEELING; CHILLS; MUSCLE ACHES; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination.The batch number was not reported and has been requested.  No concomitant medications were reported. On 11-APR-2021, the subject experienced gassy feeling. On 11-APR-2021, the subject experienced chills. On 11-APR-2021, the subject experienced muscle aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the muscle aches, chills and gassy feeling was not reported. This report was non-serious.
Approximately 2 hours post immunization, the patient states she had blotch rash around her neck and upper body. "Beginnings of hives". No shortness of breath. Went to allergist, was given single dose of singular and the symptoms subsided. States she had upset stomach for 2 days, but better now.
Shortness of breath; Soreness at injection site; Patient has had 5 Moderna vaccines in total; This spontaneous case was reported by a patient and describes the occurrence of DYSPNOEA (Shortness of breath), VACCINATION SITE PAIN (Soreness at injection site) and EXTRA DOSE ADMINISTERED (Patient has had 5 Moderna vaccines in total) in a 73-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 16-Sep-2022, the patient experienced EXTRA DOSE ADMINISTERED (Patient has had 5 Moderna vaccines in total). On an unknown date, the patient experienced DYSPNOEA (Shortness of breath) and VACCINATION SITE PAIN (Soreness at injection site). At the time of the report, DYSPNOEA (Shortness of breath) had not resolved, VACCINATION SITE PAIN (Soreness at injection site) was resolving and EXTRA DOSE ADMINISTERED (Patient has had 5 Moderna vaccines in total) outcome was unknown.      Concomitant medications details were not reported by the reporter.  On an unspecified date patient received first dose, first booster dose and second booster dose of monovalent COVID-19 vaccine moderna and on 13-Mar-2021, patient received the second dose.  Patient reported shortness of breath which started a couple of days ago, Patient did not had all the Lot numbers or dates except for date of second dose and Lot and date for Bivalent Booster. Patient has not sought any medical attention.  Treatment details were not reported by the reporter.
27 weeks pregnant at time of initial test; Tested positive for COVID-19; Tested positive for COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40-year-old female patient (pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient was 27 weeks pregnant at the event onset. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MATERNAL EXPOSURE DURING PREGNANCY (medically significant), outcome "unknown", described as "27 weeks pregnant at time of initial test"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Tested positive for COVID-19". The patient underwent the following laboratory tests and procedures: Body temperature: 100'; Oxygen saturation: no lower than 92; SARS-CoV-2 test: Positive, notes: Tested positive for COVID-19; Negative, notes: Negative test achieved on day six. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: tested positive for COVID-19 on an unspecified date. The patient was 27 weeks pregnant at time of initial test. Symptoms included fever around 100' for several days, pulse ox measurements of no lower than 92% over the course of two weeks, chest cough with persistent congestion on-going. The patient then received PAXLOVID five-day course, which was started 30 hours post positive test. Negative test achieved on day six after start of anti-viral treatment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52-year-old male patient received BNT162b2 (BNT162B2), on 14Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for Covid-19 immunisation; CoviD-19 vaccine miRNA (miRNA 1273) (COVID-19 VACCINE MODERNA), on 14Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for Covid-19 immunisation; CoviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for Covid-19 immunisation. The patient's relevant medical history included: "Penicillin" (unspecified if ongoing); "Gout" (unspecified if ongoing); "fatty liver" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing). Concomitant medication(s) included: Pravachol; Zetia; Allopurinol. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of drug ineffective, Covid-19. Clinical course: Patient did take other medication in 2 weeks. Patient took Paxlovid as treatment for COVID-19 and treatment start date was 18May2022, and stop date was 22May2022. Covid was rebound 3 days after finishing Paxlovid. Symptoms (fever, aches, congestion) and positive test. The rapid home tests had been very light after Paxlovid and are now dark. Adverse events start date was 26May2022 and was not recovered without treatment. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Pain started at the spot I was given the injection. I have a knot about a size of a dime. When you touch it the pain is unbearable. The pain is now to my shoulder and goes to my fingers, cant put my arm over my head and is constantly hurting.  I put heat on it and that didn't help. Its been 6 months and still not better some days I think its worse.
Pt received both Flu and PNEUMOVAX 23 shots on the samd day. She came back to the pharmacy next morning to report swelling, pain, redness on right armpit. She also has a hx of breast cancer.
Fatigue, headache, chills, shivering. Onset was 6 hours after vaccine administration and resolved after 1 day of bed rest.
Left arm numb, weak  and tingling interfering with sleep and  activities since Sunday (3 days now).   When given the shot  it hurt really bad and pharmacist said she must have hit a nerve.
Patient presented to the ED and subsequently hospitalized for cellulitis of left lower leg. Patient received booster dose while hospitalized.
This spontaneous report was received from a medical assistant regarding a patient of unknown age and gender. The patient's medical history, current conditions and concomitant medications were not reported. On 31-OCT-2016, the patient who was indicated to receive ZOSTAVAX (dose, route and lot number were not reported) accidentally received a dose of VARIVAX (dose, route and lot number were not reported) instead of ZOSTAVAX. There were no adverse effects reported. There was no product quality complaint involved. Additional information has been requested.
This spontaneous report as received from registered nurse refers to a patient of unknown demographics. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 05-NOV-2018, the patient was vaccinated with expired dose of RECOMBIVAX HB lot # L044917, expiry date 05-OCT-2018, administered intramuscularly for prophylaxis (exact dose was not reported). No adverse effects were reported. The outcome of the event was unknown.
TINGLING IN BOTH LEGS FROM THE KNEES DOWN; COUGHED UP BLOOD (TASTED BLOOD AND SPIT UP BLOOD); DIZZINESS; BLURRED VISION; SWEATS; INTERMITTENT CHEST PAIN; SHORTNESS OF BREATH UPON EXERTION; HEADACHE; This spontaneous report received from a patient concerned a 42 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: Patient had no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, and expiry: UNKNOWN) dose was not reported, administered on 10-SEP-2021 for prophylactic vaccination.  No concomitant medications were reported.  On 10-SEP-2021, the patient experienced dizziness. On 10-SEP-2021, the patient experienced blurred vision. On 10-SEP-2021, the patient experienced sweats. On 10-SEP-2021, the patient experienced intermittent chest pain.  On 10-SEP-2021, the patient experienced shortness of breath upon exertion. On 10-SEP-2021, the patient experienced headache.  On 28-SEP-2021, the patient experienced coughed up blood (tasted blood and spit up blood). Laboratory data included: Blood test (NR: not provided) could not find anything wrong, and Chest X-ray (NR: not provided) could not find anything wrong. On 03-OCT-2021, the patient experienced tingling in both legs from the knees down. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from tingling in both legs from the knees down, and the outcome of headache, dizziness, blurred vision, sweats, coughed up blood (tasted blood and spit up blood), intermittent chest pain and shortness of breath upon exertion was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment is not required as per standard procedure as case is assessed as non-serious.
High fever after receiving does #3 of anthrax vaccination...104.5 and chills with night sweats for 2 days.
Three weeks into the vaccine, I ended up having shortness of breathe when I laid down. It has eased up now a little. I started having an intermittent cough due to the vaccine (felt like my lungs were not feeling great) This occurred during the evening and at night when I would lay down to rest. I had a fairly mild case of COVID-19 (tested at the beginning) and quarantined for three weeks. A month later I took the blood test for antibodies (actually had COVID-19 last June which is nearly a year ago before taking the Janssen vaccine). My blood sugar is off the charts and my blood pressure has elevated since taking the vaccine (reason for awaiting an appointment with my doctor).
PATIENT RECIEVED A THIRD MODERNA VACCINE DOSE ON 6/8/21 . FOLLOW UP TRAIGE CALL ON 6/18/21 PATIENTS REPORTS NO LOCAL OR SYSTEMATIC SIGNS OR SYMPTOMS
No additional AE reported; 1 dose of ROTATEQ was administered following a temperature excursion / temperature 50 F; This spontaneous report was received from a physician and refers to a patient of unknown age and gender. There was no information regarding their medical history, concurrent conditions nor concomitant therapies provided.  On 08-OCT-2021, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 1 dose orally, lot # 1707572, expiration date 11-MAR-2022 for prophylaxis (product storage error). The administered vaccine was stored in a temperature of 50 degrees Fahrenheit (F) for 39 hours and 47 minutes. No previous temperature excursion occurred. No adverse event (AE) was reported.
pt recvd vax & exp a rash of upper lt arm & upper lt lip; addtl arm was sore; pt stated that reacted liked this to PCN on a 2nd shot;
Patient is 12 years old and was given DTaP Infanrix. Patient had no adverse reaction.
This spontaneous report was received from a physician via a company representative referring to a 14 year old male patient. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were unknown by reporter. On 26-FEB-2018, the patient was vaccinated with the first dose of GARDASIL 9 0.5 ml, intramuscularly, for Human Papillomavirus (HPV) prevention (strength, lot # and expiration date were not reported). On that same date, while patient was waiting post vaccination, he fainted, having a syncopal episode, two times. The physician stated one of the times patient fell, he was out of a chair, but there was no sign of any injury. The physician also stated that patient did not need treatment and stayed in the doctor's office under observation for one hour. No any laboratory study was performed. At the reporting time, the patient was recovered from the syncope and the fall. The causality assessment between the events and vaccination with GARDASIL 9 was not provided.
Neck weakness and pain with noted difficulty in rotating head from left to right and vice versa. 1-2 weeks later full body fatigue and constant pain radiating down left shoulder/arm.
right deltoid injection. Started feeling dizzy and mild CP for a couple of minutes which has since subsided. Patient now having involuntary muscle spasms to opposite(left) arm.
Initial and follow up information has been received from a registered nurse concerning an 80 year old retired female patient, with multiple drug allergies (codeine ("codine"), quinine, cyclobenzaprine hydrochloride (FLEXERIL), acetaminophen (+) hydrocodone bitartrate (Lortab), celecoxib ("CELEBRAN" CELEBRA), and acetaminophen (+) propoxyphene napsylate (DARVOCEY-N), who at 11:20 am on 17-JAN-2006 was vaccinated intramuscularly in the left deltoid with a dose of pneumococcal 23v polysaccharide vaccine (Lot# 651330/1048P). On 17-JAN-2006 the patient developed severe, local cellulitis-like reaction. Follow up information indicated that on the evening of 17-JAN-2006 the patient developed painful, swollen, red left arm, that also itched. The patient was treated with cephalexin (KEFLEX) 250 mg and desloratadine (CLARINEX) 5 mg. There was no illness at the time of vaccination. No product quality complaint was involved. On an unspecified date the patient recovered. Additional information is not expected.
Sore Arm; Slight headache; Chills on/off; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore Arm), HEADACHE (Slight headache) and CHILLS (Chills on/off) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21-2A) for COVID-19 vaccination.     The patient's past medical history included Weight loss (chills with were with weight loss ( prior to vaccine).) and Chills (chills with were with weight loss ( prior to vaccine).).    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore Arm), HEADACHE (Slight headache) and CHILLS (Chills on/off). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Sore Arm), HEADACHE (Slight headache) and CHILLS (Chills on/off) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.    This case was linked to MOD21-063420 (E2B Linked Report).; Sender's Comments:  MOD21-063420:MOD-2021-059848 -1st Vaccine Dose of Husband